Type 2 Diabetes

ACP Defends Higher Blood Glucose Targets for Type 2 Diabetes

ACP responds to criticism from the ADA, the Endocrine Society, the AACE, and the AADE of guidance that clinicians should aim to achieve an HbA1c ...

Case for Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes

An increasing number of studies support the use of continuous glucose monitoring in adult patients with T2D, and the observed benefits are likely to extend ...

Ask the Experts: Dr Goyal on SGLT2 Inhibitors

Dr Goyal from NYU Langone Health in New York City talks about SGLT2 inhibitors in the treatment of type 2 diabetes.

Addressing Psychological Insulin Resistance in Patients With Diabetes

Learn about strategies to reduce a patient's reluctance to initiate insulin therapy, a phenomenon called psychological insulin resistance.

Managing Type 2 Diabetes: The Impact of Secure Patient-Provider Messaging

Secure messaging presents an opportunity for patients and healthcare providers to collaborate on self-management issues like glycemic control, diet, and exercise.

In-Hospital Tramadol Use Increases Hypoglycemia Risk in T1D, T2D

Results indicate that blood glucose monitoring should be conducted in hospitalized patients with diabetes.

Type 2 Diabetes and Antidepressant Drug Use: Is There a Causal Link?

Updated meta-analysis confirms the association between antidepressant drug (AD) use and incident diabetes. Future studies should be aimed at evaluating the effect of single AD ...

Video

Latest Headlines

DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes

DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes

Investigators sought to determine whether the use of dipeptidyl peptidase-4 inhibitors is associated with the incidence of rheumatoid arthritis.

Healthy Lifestyle With Diabetes Cuts Cardiovascular Risk

Healthy Lifestyle With Diabetes Cuts Cardiovascular Risk

Greater adherence to an overall healthy lifestyle is associated with a substantially lower risk for cardiovascular disease.

Diabetes Treatments

Antidiabetic agents for the treatment of diabetes including maintenance and max doses.

Sitagliptin May Improve Glycemic Control Better Than Dapagliflozin in T2D With Mild Renal Insufficiency

Sitagliptin May Improve Glycemic Control Better Than Dapagliflozin in T2D With Mild Renal Insufficiency

The safety and efficacy of sitagliptin vs dapagliflozin in patients with type 2 diabetes and renal insufficiency was examined.

Intermittent vs Continuous Energy-Restricted Diet: Effects on Glycemic Control and Weight Loss T2D

Intermittent vs Continuous Energy-Restricted Diet: Effects on Glycemic Control and Weight Loss T2D

Intermittent energy restriction diet may be an effective alternative diet strategy for reducing HbA1c in patients with type 2 diabetes.

Second-Line Therapies Show Benefit Over Metformin Monotherapy in T2D

Second-Line Therapies Show Benefit Over Metformin Monotherapy in T2D

Investigators assessed the effect of second-line therapies on weight, HbA1c, and treatment persistence over 18 months in patients who had received metformin monotherapy.

Dapagliflozin Plus Omega-3 Carboxylic Acids for Non-Alcoholic Fatty Liver Disease in T2D

Dapagliflozin Plus Omega-3 Carboxylic Acids for Non-Alcoholic Fatty Liver Disease in T2D

Combination treatment with dapagliflozin plus omega-3 carboxylic acids may reduce fat content in nonalcoholic fatty liver disease.

One in Four Older Adults With Diabetes Uses Alternative Meds

One in Four Older Adults With Diabetes Uses Alternative Meds

More than 25 percent of older U.S. adults with diabetes use some type of complementary and alternative medicine.

HbA1c-Corrected FRAX Score May Better Predict Fracture Risk in Type 2 Diabetes

HbA1c-Corrected FRAX Score May Better Predict Fracture Risk in Type 2 Diabetes

A corrected HbA1C factor may improve the ability to predict the risk for fracture by the FRAX algorithm in T2D.

Estimating Risk Factors and Trajectories for Diabetic Polyneuropathy

Estimating Risk Factors and Trajectories for Diabetic Polyneuropathy

Investigators examined cardiometabolic risk factor trajectories in patients diagnosed with type 2 diabetes over the course of 13 years preceding diabetic polyneuropathy.

Sign Up for Free e-Newsletters



CME Focus